Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GSK Expected to Buy Nanjing MeiRui Pharma

publication date: Dec 2, 2010
According to well-placed sources, GlaxoSmithKline will soon acquire Nanjing MeiRui Pharma Co., a China company specializing in the urology market. The price is rumored to be in the low hundreds of millions of dollars. Both companies are active in the urology market, with drug products that address benign prostatic hyperplasia. GSK is expected to announce the deal before the end of the year. More details....

Stock Symbol: (NYSE: GSK)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital